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AbstractSummary 
Antimicrobial resistance is now recognised as a threat to health worldwide. Antimicrobial 
stewardship (AMS) aims to promote the responsible use of antibiotics and is high on international 
and national policy agendas. Health information technology (HIT) has the potential to support AMS 
in a number of ways, but this field is still poorly characterised and understood.  Building on a recent 
systematic review and expert roundtable discussions, we take a lifecycle perspective of antibiotic 
use in hospitals and identify potential targets for HIT-based interventions to support AMS.  We aim 
for this work to help chart a future research agenda in this critically important area. 
 
Introduction  
Antimicrobial resistance is now recognised as an urgent global threat to health.1 The prevalence of 
single- and multi-drug resistant organisms is increasing2 as is mortality due to infections caused by 
these organisms.3 Across the European Union (EU) and the Unites States (US), antimicrobial-resistant 
infections are responsible for at least 50,000 deaths annually.4, 5 Globally, these infections claim an 
estimated 700,000 lives each year.6  
Antimicrobial Stewardship (AMS) is the international response to the threat of resistance. As the 
inappropriate use of antibiotics is a key contributor to resistance,7 there is increasing policy and 
clinical interest to promote appropriate use of antibiotics8 through a set of concerted interventions, 
including: health information technology (HIT),9 guidelines and protocols,10 education and training, 
and novel staffing structures in the form of antimicrobial committees and champions.11 Together, 
Often used in combination, these interventions aim to optimise the use of antibiotic therapy,12 
reduce resistance, minimise hospital acquired infections, and improve clinical outcomes.13  
HIT has much to offer the AMS agenda as can be seen by the increasing number of studies that have 
looked into the feasibility, effectiveness, and accessibility of various HIT-mediated AMS 
interventions.9, 14, 15 There is however a lack of any comprehensive overview of the potential targets 
for HIT-based interventions. This may hamper progress in this still nascent, but critically important 
field.  
The aim of this article is to highlight areas of the antibiotic lifecycle that are potentially most 
amenable to HIT interventions in hospital settings. This review also outlines HIT that has the 
potential to be deployed in relation to AMS, and is currently, or soon to be, available.  We do not, 
however, make claims that this HIT is unequivocally helpful.  Further, this review is not exhaustive 
but intends to invite discussion around which of these areas may be implementable and 
subsequently scalable in hospital AMS programmes in the UK and to identify areas for further 
research enquiry. 
 
Methods 
We began by developing a conceptual schema of all stages of an archetypal antibiotic lifecycle from 
the initial decision to prescribe an antibiotic for a patient with suspected infection, through to the 
review of treatment within a typical UK hospital setting (Figure 1). This antibiotic lifecycle was 
informed by a review of the published and grey literature, and multidisciplinary discussions involving 
patients, hospital clinicians and management staff undertaken as part of our ongoing programme 
grant of hospital electronic prescribing (ePrescribing) systems.  More specifically, we drew on our 
recent systematic review14 and expert multi-stakeholder roundtable discussion,16 which highlighted 
the many ways in which HIT already supports, and could potentially support AMS by applying best 
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practice technologies and procedures during the antibiotic lifecycle in UK hospital care. We 
conceptualised this work within the context of the UK policy framework for AMS: Start smart - then 
focus.17 
 
Lifecycle of hospital antibiotic use 
The lifecycle of antibiotic management in hospital starts when a patient presents to hospital with or 
develops during their hospital stay a suspected infection. The lifecycle (Figure 1) proceeds through 
an initial differential (working) diagnosis from the initial presentation, obtaining specimens for 
microbiological cultures and sensitivity testing (where applicable), initial empirical treatment 
decision and generation of a prescription order, followed by timely review of treatment and 
subsequent amendment where applicable. This is far from a linear process; it typically involves many 
different ‘actors’ at different points in the care process, and each process is variable depending on 
patient demographics such as prior history and comorbidities. As such, to understand how the AMS 
agenda can be supported with HIT, it is important to consider the clinical situations that fall outside 
the lifecycle and how these too may be supported through appropriate HIT intervention.  In the 
sections below we discuss the components that already are supported and those that can be 
supported by HIT to better align care with the AMS agenda. At present, some of these HIT 
interventions are commonly seen across hospitals in the UK, EU and US, while others have been 
employed by only a few benchmark hospitals. 
 
Potential for HIT interventions to promote AMS  
Health systems are moving towards digitisation.18 The ability to store, share, access, and proactively 
use information at the point of care as well as through prospective and retrospective auditing and 
feedback is being used to drive forward efforts to enhance the safety, quality, and efficiency of 
healthcare.19 HIT that supports AMS can come in many forms: electronic health records (EHRs) that 
record patient information such as diagnoses and previous medication sensitivities; ePrescribing 
systems, such as computerised physician order entry (CPOE) and/or clinical decision support (CDS) 
systems;20 and monitoring systems that draw together information from disparate parts of the 
hospital, enabling, for example, the triaging of patients who require clinical intervention. These 
systems can make data accessible to support diagnosis, treatment decisions, and review of patients 
who may for example need the route of delivery of antibiotics to be changed (e.g. intravenous to 
oral) or those in whom treatment can be discontinued.13  
In the subsequent sections, Wwe describe particular points in the antibiotic lifecycle that may be 
supported by and optimised through HIT intervention (also delineated in Figure 2). These sections 
reflect the Start smart – then focus17 framework as it is the recommended approach by Public Health 
England for all antibiotic prescribing. The Iinterventions described mainly target clinical staff: 
doctors, pharmacists, and nurses at the point of care, as well as at the level of an AMS committee or 
hospital management.  They may in the future also target patients/carers.  
 
Start Smart 
(a) Patient presentation  
At its simplest, the lifecycle of a hospital administered antibiotic starts when a patient presents with 
symptoms suggestive of an infection or develops a new infection whilst already in hospital. A 
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clinician will take (or review) the patient’s medical and drug history, undertake a physical 
examination, and perform relevant investigations, including blood tests. This process and 
information can be documented in the EHR alongside the patient’s current regimen of medication 
and any known allergies to medications. Through the EHR, the clinician may also access the patient’s 
previous microbiological results with any antimicrobial resistance data that may help inform 
assessment of the likely effectiveness of the antibiotic(s).  
(b) Diagnosis   
The clinician will make a differential diagnosis, and if an infectious process is suspected then a 
decision will be made whether to commence empirical treatment with a relevant antibiotic. 
Decisions can be documented in the EHR along with the suspected indication and proposed duration 
of any treatment. The diagnosis may also be documented in the ePrescribing system if this is 
separate to the EHR.  As EHRs and ePrescribing systems are often integrated, the patient information 
and indication for treatment21 can be easily accessed as is the ability to track the progress of the 
patient and the clinical decision making over time. However, not all information may be in a form 
that allows for this tracking of decision making processes over time – this is because the initial 
diagnosis may not be recorded or indications may not be reported in a structured way that can be 
used to drive reports. Further research using natural language processing (NLP) may prove helpful in 
such scenarios.  
(c) Obtain cultures 
An important step in the antibiotic prescribing process is, where appropriate, obtaining cultures to 
determine the organism responsible for the infection. Importantly, cultures should be obtained 
before starting treatment, although this should not delay the initiation of antibacterials in cases of 
suspected sepsis. This  Culture resultsinformation can confirm whether any empirical treatment 
commenced is appropriate to continue, or whether treatment needs to be changed for optimal 
management (or started if not done so previously). Through understanding local resistance patterns 
and susceptibility rates of particular organisms, clinicians can determine which antibiotics might 
work for the particular infection and also whether the chosen antibiotic(s) is likely to work in any 
individual patient.  
HIT can play an important role here. By linking culture orders, medication orders and administration 
records, HIT by mediating supports the communication between the prescribers on the wards and 
the microbiologists in the laboratory. Further, Mmicrobiology results can be incorporated into the 
EHR and made available at the point of care. Systems can alert prescribers to results that have 
recently been made available, in order to prompt action for review. However, as these results often 
rely on free text data, the multiplicity of report formats mean that microbiology results are often not 
yet in a form that can be used to drive more specific alerts, such as when the organism causing a 
patient’s infection is resistant to the antibiotic the patient has been prescribed. Coding for urgency 
in alerts prompted by available microbiology data is an important area of future HIT development.  
(d) Initial treatment decision 
While awaiting the results of cultures and antibiotic sensitivity tests, clinicians will typically institute 
an empirical treatment plan based on the differential diagnosis. Minimising exposure to broad-
spectrum antibiotics and maximising exposure to optimal therapies is an important component of 
AMS.22 The initial treatment decision and prompt initiation for specific indications (e.g. ventilator-
associated pneumonia)23 and in specific hospital care contexts (e.g. critical care units)24 is another 
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strategic area for AMS, however, this may be in tension with the judicious use of antibiotics until 
culture results are available.13   
ePrescribing systems can facilitate access to local antimicrobial prescribing guidelines designed to 
support practitioners in selecting the most appropriate first-line antibiotic, at a suitable route, dose, 
frequency, and duration for the specific patient and indication. Guidelines can be accessed via EHRs 
alongside updated formularies, supporting clinicians in selecting antibiotics that are locally approved 
and available. For certain clinical situations, such as surgical prophylaxis and post-operative care, HIT 
systems can also facilitate access to standardised local protocols via electronic order sets. These are 
aggregated collections of orders or steps to follow for a given condition or clinical situation that can 
support evidence-based practice for the judicious use of antibiotics. Procedures for prior 
authorisation of restricted antibiotics can also be built into the HIT-mediated prescription process. 
This may require the review and approval by a member of the AMS committee or specialist 
infectious disease (ID) doctors before a prescription can be ordered and thus prepared for 
administration. If a restricted agent is prescribed, the prescriber may be presented with a list of 
alternative options from the formulary and guidelines as well as the contact information for the 
person who can authorise the order. The HIT system can also alert relevant approving individuals 
that a restricted antibiotic has been ordered and can provide them with the relevant patient and 
prescription information to either accept or decline the prescription. For complex cases, the HIT 
system can support prompt communication between the patient care team and specialist ID doctors, 
facilitating shared prescription decisions as well as immediate authorisation for restricted agents. 
Treatment decisions can also be informed by antibiograms (Table 1) that provide practitioners with 
real-time, local profiles of antibiotic susceptibility and resistance patterns for specific organisms (Box 
1, Example 1).  
HIT can further support initial treatment decisions by enabling the clinician to document their 
decision including the drug name, route, dose and frequency in the EHR and/or ePrescribing 
systems. With this information, HIT can aid with indication-based prescribing, dose/frequency 
checking, as well as allergy, drug-disease interaction and drug-drug interaction checking. 
ePrescribing systems can also encourage the use of appropriate, evidence-based antibiotic therapies 
through behavioural nudges.25 At the point of care, nudges can come in the form of ‘accountable 
justification’ and ‘suggested alternatives’, as described by Meeker et al (2016). Accountable 
justification, through prompts within the ePrescribing system, requires clinicians to explain their 
selection of antibiotics in a free text box that is ultimately included in the patient’s EHR.  Suggested 
alternatives, through pop-up alerts, are triggered when antibiotics are prescribed for conditions that 
may be treated through other therapeutic routes. These alerts can provide prescribers with a list of 
alternative therapies as well as easy access to electronic order sets for these therapies.  
(e) Prompt initiation of effective treatment supported by EHR 
The interoperability and automation of HIT systems aim to minimise the time from the diagnostic 
order to the patient receiving the first dose.26 During prescription preparation, HIT can support 
pharmacists through a process of controls: checking whether the prescription is appropriate for the 
indication and the patient as well as facilitating contraindication checks such as allergies, drug-
interactions and conditions such as renal impairment which may necessitate a modification of the 
antibiotic dose. EHR and ePrescribing systems can also support nurses during the administration of 
medication through reminders for timely administration as well as alerts for missed and delayed 
doses.  
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Then Focus 
(a) Reviewing the clinical diagnosis and assessing the need for continuing antibiotics 
The National Institute for Health and Care Excellence (NICE) recommends that prescriptions for 
antibiotics are reviewed 48 to 72 hours after initiation.27 The purpose of the review is to determine:  
• Whether the patient has an infection that will respond (or is responding) to antibiotics; 
• Whether the patient is on the correct antibiotics (as well as if the therapy is at the right 
route and dose of administration);  
• If a more targeted antibiotic can be used (especially if a narrower spectrum antibiotic will be 
sufficient);  
• And, how long the patient should receive the antibiotic treatment.  
Importantly, this review is performed alongside the culture and sensitivity data provided by the 
microbiology laboratory. These data will also provide information on drug resistance as well as the 
sensitivity of antibiotics to the isolated organism. If changes are deemed necessary following the 
review, there are several potential actions available: continuing treatment, stopping therapy, 
switching the route, changing the antibiotic, or discharging the patient with a continued course of 
antibiotics.  
The review and subsequent changes to antibiotic treatment should occur in a timely manner, as 
soon as culture results are available or if the patient’s condition is altering. HIT can support this 
process by alerting clinicians to view the results or by providing reminders that a review is required. 
HIT can further alert clinicians to these consider potential actions: for example, switching to an 
alternative therapy in the presence of a drug-organism mismatch, or switching from IV to oral 
antibiotics when the patient is eating/drinking/taking other treatments orally and appropriate 
treatments are available to take by mouth. These alerts can help to reduce the time between the 
availability of culture results and the review of antibiotic treatment. This is particularly important for 
AMS efforts as switching from initial therapy to a more optimal, appropriate therapy can minimise 
deleterious effects to patient health,15 contribute to an earlier discharge,9 minimise cost,13 and 
reduce the risk of resistance.13 HIT can further support review and subsequent therapeutic changes 
by facilitating access to relevant protocols: e.g. extended infusion of antibiotics, parenteral to oral 
switch or Out-Patient Antibiotic Therapy (OPAT). However, further research is needed to explore 
how HIT can support the behavioural components involved in reviews as healthcare professionals 
can be reluctant to revisit and change a decision previously made by a doctor. 
(b) Review by AMS champions 
Alongside the work of individual practitioners in the medication process, AMS programmes are more 
effective when driven by a focused group of healthcare professionals.13 Often termed the AMS 
Committee, or AMS Champions, this group supports many components of the AMS agenda (Figure 3) 
including the provision of face-to-face specialist review or support to clinical teams during complex 
patient cases. Important to the work of committees and champions is the ability to have oversight of 
all antibiotic prescriptions across the hospital.  This oversight can be considerably enhanced through 
the use of monitoring systems (Box 1, Example 2).  These systems can aggregate and organise data 
from many sources across the hospital into actionable alerts. Data can come in the form of 
resistance and susceptibility information, as well as information about patients, treatments, and 
indications. AMS committees can gain an overview of all patients on antibiotic therapy through 
these systems. The most urgent cases can also be made visible, enabling the prioritisation of patient 
review.   
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AMS committees also update antimicrobial guidelines and protocols, and inform the formularies that 
can be made available within the EHR. Further, committees can monitor adherence to guidelines and 
protocols with the help of HIT to identify wards, clinical teams or individual prescribers who may 
require further support as well as to inform the update of hospital policies. 
 
Over longer timeframes (months to years), collecting and reusing data 
As discussed above, HIT has much to offer the AMS process at the point of care.  Many components 
of the AMS agenda can also provide benefits over longer timeframes, especially those supported by 
HIT. EHRs and ePrescribing systems can aggregate longitudinal prescribing data at multiple levels: 
individual clinicians, clinical teams, wards, and hospitals. This enables comparison of inappropriate 
prescribing rates (Box 1, Example 3). Meeker et al (2016) describe an intervention based on 
behavioural economics that contacted each prescriber via email reporting whether the prescriber 
was a “Top Performer” or “Not a Top Performer”, as defined by their proportion of inappropriately 
prescribed antibiotics. Due to the positive reinforcement and social motivation behind this 
intervention, inappropriate antibiotic prescribing was significantly reduced. 
Over longer timeframes, HIT can also enable further audit and feedback, monitoring, and 
benchmarking of antimicrobial prescribing practice. These functions can support clinicians, 
pharmacists, and AMS committees in further promoting the AMS agenda as well as lead to inter-
hospital comparison. For example, in the UK there is a national benchmark indicator derived in many 
hospitals from HIT data to compare the total consumption of carbapenem antibiotics (a broad 
spectrum class agent) per 1,000 admissions as part of the NHS Commissioning for Quality and 
Innovation (CQUIN) targets in 2016/17.28 Ultimately, data-driven surveillance can help to better 
define and direct effective AMS strategies, as well as continuously assess hospitals systematically at 
the local, regional, national, and international level. 
These developments over longer timeframes can all feed back into HIT systems to further optimise 
future therapeutic decisions, improve outcomes, and reduce resistance to antibiotics.  
 
The future of HIT-mediated AMS 
There exist many further areas of HIT support that are either in the early stages of evaluation in pilot 
hospitals or are still in the development pipeline. Many of these involve the improvement of existing 
system design to more accurately transmit actionable information throughout the hospital (such as 
the potential for specific microbiology results to prompt urgent alerts, as discussed above).  
Predictive modelling29 is another emerging possibility for AMS support that has the potential to 
optimise the initial prescription of antibiotics.  By bringing together information regarding an 
individual patient’s risk factors for resistance and susceptibility to certain antibiotics, predictive 
modelling tools may aid in the selection of optimal antibiotic therapy at the level of the prescriber. 
Point-of-care diagnostic tests also offer the possibility of selecting optimal routes of care on the 
ward through the rapid identification of infectious agents. 
HIT can also enable further data collection for audit and feedback. These data are important for 
benchmarking hospitals against others to evaluate AMS interventions and to better understand the 
barriers and facilitators to implementation.  
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Cloud-based EHRs are on the horizon which will raise the possibility of expanding HIT support from 
the antibiotic prescription and review lifecycle on the ward to an extended antibiotic lifecycle: one 
that follows patients through their hospital admission, discharge, and back into the community. 
Further support in the community is expected to come in the form of patient access to information 
and education about appropriate treatment and avoiding overuse of antibiotics. These approaches 
can also support those in the community who have different needs around antibiotics, such as 
expert patients with long-standing conditions (e.g. for a patient with cystic fibrosis, the timely 
administration of antibiotics is often more important than avoiding overuse of antibiotics). With the 
aim of empowering patients and involving them in the decision-making process around antibiotics, 
patients will soon be able to access information about their resistance patterns.30 
 
Conclusions 
AMS is a national and global priority being implemented to reduce the risk of antimicrobial 
resistance. HIT is both maturing and converging, and as a result offers considerable opportunities by 
supporting: access to relevant data (e.g. personal and local antibiotic resistance patterns) and 
antimicrobial guidelines, documentation of diagnoses, initial selection of empirical treatment, 
review, audit and feedback, and monitoring.  The most effective HIT-enabled AMS interventions are 
likely to be multi-faceted, consisting of many of these different components in tandem with 
behavioural changes. Importantly, any implementation requires careful planning and integration 
with existing systems, as well as staff engagement and participation. HIT processes alongside 
education, training, and person-person interaction between staff as well as with patients will be 
most effective in comprehensively supporting AMS.  
This paper provides a starting point for how these components may be conceptualised alongside the 
existing processes surrounding antibiotic prescription and review. Research in this area needs to be 
prioritised in order to ensure that the considerable potential offered by developments in HIT in 
relation to AMS are realised in a timely fashion.  
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Figure 1. Conceptual schema of an archetypal antibiotic lifecycle through prescription and review within a UK hospital setting.  
 
 
 
 
 
Comment [KA15]: Changed 
"previous resistance" to "local 
resistance patterns in response to 
reviewers comment: Figures 1 and 2 
– in the section on antimicrobial 
stewardship, the phrase “previous 
resistance” should be written as 
“personal resistance patterns” as 
described in the text, as I initially 
thought that this referred to local 
resistance patterns.  
We have added “local” to the text to 
qualify the resistance patterns rather 
than “personal” as the latter is not a 
commonly utilised description in 
practice.  
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Figure 2. HIT support of the antimicrobial stewardship agenda. 
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Table 1. Hypothetical antibiogram of Gram negative and Gram positive isolates from urine cultures. 
Antibiograms summarise antibiotic susceptibilities in order to facilitate the selection of appropriate antibiotic 
therapy. In the past, antibiograms were updated annually. Presently, through the help of HIT, antibiograms are 
updated continually as new susceptibility data becomes available. Antibiograms can be filtered to show prescribers 
susceptibility patterns for the region, the institution, and the ward.  
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Box 1: Clinical examples of inappropriate use of antibiotics targeted and remedied by HIT intervention 
Examples draw on preliminary explorative work investigating HIT-enabled AMS strategies in international benchmark 
hospitals.  
Example 1: Antibiogram  
Antibiograms are available on smart phones and accessible to prescribers at the point of care. Clinicians at one large, 
city hospital use antibiograms to look up antimicrobials and infectious organisms to get a real time sense of resistance 
patterns, either within the whole hospital or specifically on a single unit. Antibiograms also provide clinicians at this 
hospital with sensitivity data of specific vectors in their health system to specific antibiotics. This is helpful when 
selecting initial antibiotic treatment for a patient whilst awaiting cultures and sensitivities.  
Example 2:  HIT enables a focused review of patients on antimicrobials 
At one academic medical centre, a monitoring system organises microbiology results alongside prescription, diagnosis, 
and patient data. This system alerts members of the stewardship team to situations where antimicrobials have the 
potential to be optimised. This robust system of alerts can capture most concerns related to AMS by organising 
information and focusing AMS efforts to where they are most needed. Before the implementation of this monitoring 
system, pharmacists at this hospital had to review all antibiotic prescriptions to find an intervention. This took a great 
amount of time and resulted in the absence of review for some of the most complex and high risk cases. With the HIT 
system in place, pharmacists gain an overview of all patients on antimicrobials as well as knowledge of which patients 
need to be prioritised.  
Example 3: HIT enables reporting of antimicrobial usage 
At one of the pioneer hospitals in AMS, HIT enables intervention on the level of the user by reporting antimicrobial 
usage of individual prescribers and wards. Prescribing statistics are reported to individual clinicians, benchmarking 
them against their peers. Reporting encourages personnel to become engaged in the stewardship process and to 
expand the reach of the AMS programme. 
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Figure 3. Support of the antimicrobial stewardship agenda through AMS committees and champions. 
 
 
 
